Thermopeutix Inc San Diego, CA - 92131

Thermopeutix Inc is categorized under Commercial Medical Research in San Diego, CA and active since 2008.

Thermopeutix Inc was established in 2008, and today employs 1 to 4, earning $2.500.000 to $4.999.999 per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 3391120 by the NAICS.

If you are seeking more information, feel free to contact Glen Liber, Chief Executive Officer at the company’s single location by writing to 9951 Businesspark Avenue # B, San Diego, California CA 92131 or by phoning (858) 549-1760. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Thermopeutix Inc
Contact Person: Glen Liber, Chief Executive Officer
Address: 9951 Businesspark Avenue # B, San Diego, California 92131
Phone Number: (858) 549-1760
Annual Revenue (USD): $2.500.000 to $4.999.999
Founded: 2008
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Commercial Medical Research
SIC Code: 8731
NAICS Code: 3391120
Share This Business:

Thermopeutix Inc was started in 2008 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 3391120. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $2.500.000 to $4.999.999 per annum.

Feel free to contact Glen Liber, Chief Executive Officer for inquiries that concern Thermopeutix Inc by calling the company number (858) 549-1760, as your correspondence is most welcome. Additionally, the physical location of the single location of Thermopeutix Inc can be found at the coordinates 32.90467,-117.11144 as well as the street address 9951 Businesspark Avenue # B in San Diego, California 92131.

For its online presence, you may visit Thermopeutix Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.